Micafungin Olikla (Micafungin)

Micafungin is an echinocandin antifungal that targets Candida species in serious systemic infections.

• Invasive candidiasis: eliminates bloodstream and deep‑tissue Candida infections.
• Esophageal candidiasis: resolves fungal infection of the esophagus.
• Candida peritonitis and intra‑abdominal infections: treats Candida‑related abdominal sepsis.
• Prophylaxis of Candida infections in hematopoietic stem cell transplantation: prevents invasive fungal disease in transplant recipients.

• Micafungin inhibits the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesising β‑(1,3)‑D‑glucan, a critical structural component of the fungal cell wall. By disrupting cell‑wall formation, the drug leads to osmotic instability and fungal cell lysis, providing a fungicidal effect against susceptible Candida species.

Micafungin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Fever: transient temperature rise after infusion.
• Nausea: mild gastrointestinal upset.
• Headache: occasional mild to moderate headache.
• Elevated liver enzymes: transient increase in ALT/AST.
• Rash: mild skin erythema or pruritus.
• Infusion‑related reactions: flushing or mild hypotension.

Serious or Rare Side Effects

• Hepatic failure: rare but severe liver injury.
• Anaphylaxis: immediate hypersensitivity reaction.
• Severe hypersensitivity: including Stevens‑Johnson syndrome.
• Acute renal failure: uncommon renal impairment.
• Severe neutropenia: rare drop in white blood cells.

When using Micafungin, clinicians should consider several safety measures.

• Liver function monitoring: check ALT/AST before and during therapy.
• Renal function assessment: evaluate creatinine clearance in patients with kidney disease.
• Hepatic impairment dosing: adjust or avoid in severe liver dysfunction.
• Hypersensitivity caution: discontinue if signs of allergic reaction appear.
• Cardiac monitoring: observe for hypotension during infusion.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin may interact with other medicines; awareness of interaction severity is essential.

Major Interactions (Avoid)

• Cyclosporine: increased exposure leading to nephrotoxicity.
• Tacrolimus: elevated blood levels and risk of toxicity.
• Sirolimus: heightened immunosuppressive effect.
• Rifampin: strong enzyme induction reduces Micafungin efficacy.
• Carbamazepine: induces metabolism, lowering drug concentrations.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole): may increase Micafungin levels.
• Warfarin: potential alteration of anticoagulant effect.
• Statins: monitor for increased risk of myopathy.
• Oral contraceptives: possible reduction in hormonal efficacy.
• Phenytoin: may modestly decrease Micafungin exposure.